A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new?

Seminars in Nuclear Medicine

Volumn 41, Issue 4, 2011, Pages 246-264

  Vallabhajosula, Shankar ^a   Solnes, Lilja ^a   Vallabhajosula, Brigitte ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTIDE GA 68; 3' FLUOROTHYMIDINE F 18; 5 HYDROXYTRYPROPHAN C 11; ACETIC ACID C 11; ANNEXIN V CU 64; CHOLINE C 11; COPPER 64; FLORBETABEN; FLUCICLATIDE F 18; FLUCICLOVINE F 18; FLUORINE 18; FLUORO LEVO 2 TYROSINE F 18; FLUORO LEVO DOPA F 18; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; GALLIUM 68; GIRENTUXIMAB I 124; IODINE 124; METHIONINE C 11; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SODIUM FLUORIDE F 18; TECHNETIUM 99M; THYMIDINE C 11; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIRCONIUM 89;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIGEN EXPRESSION; APOPTOSIS; BLOOD FLOW; CELL PROLIFERATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG APPROVAL; HEART MUSCLE PERFUSION; HUMAN; HYPOXIA; IMAGING; ISOTOPE LABELING; KIDNEY CANCER; MYOCARDIAL PERFUSION IMAGING; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BONE DISEASES; BRAIN NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MYOCARDIAL PERFUSION IMAGING; NEOPLASMS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79957739301     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.02.003     Document Type: Review

References (122)

1. Ido T, Wan CN, Fowler JS: Fluorination with F2: convenient synthesis of 2-deoxy-2-fluoro-d-glucose. J Org Chem 42:2341-2342, 1977
2. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-138, 1986
3. 18F]fluoro-2-deoxy-Image-glucose. Appl Radiat Isot 47:61-66, 1996
4. International Atomic Energy Agency: Radioisotope products and their availability. Nuclear Technology Review 36-38, 2010
5. 18F-Labelled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanism of tumor localization. Semin Nucl Med 37:400-419, 2007
6. Vallabhajosula S (ed): Molecular Imaging: Radiopharmaceuticals for PET and SPECT. Berlin/Heidelberg, Springer-Verlag, 2009
7. Dunphy MP, Lewis JS: Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50(Suppl 1):106S-121S, 2009
8. 18F]FDG for use in oncology and neurosciences. Nucl Med Biol 37:727-740, 2010
9. Wadsak W, Mitterhauser M: Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 73:461-469, 2010
10. Någren K, Halldin C, Rinne JO: Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging 37:1575-1593, 2010
11. 18F-AV- 45: a PET agent for amyloid beta plaques in the brain. J Nucl Med 50:1887-1894, 2009
12. Sioka C, Fotopoulos A, Kyritsis AP: Recent advances in PET imaging for evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging 37:1594-1603, 2010
13. Shaw SM: Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol 6:569-579, 2009
14. Ghosh N, Ornella E, Rimoldi E, et al: Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J 31:2984-2995, 2010
15. Sinusas AJ: Multimodality cardiovascular molecular imaging: an overview. J Nucl Med 51:1S-2S, 2010
16. Callahan RJ, Chilton HM, Ponto JA, et al: Procedure guideline for the use of radiopharmaceuticals 4.0. J Nucl Med Technol 35:272-275, 2007 (Pubitemid 350232331)
17. Positron emission tomography (PET): products, safety and effectiveness of certain PET drugs for specific indications. Fed Regist 65: 12999-13010, 2000
18. Draft guidance on the content and format of NDAs/ANDAs for certain PET drug Products: FDG F-18 injection, ammonia N 13 injection, and sodium fluoride F-18 injection. Fed Regist 65:13010-13012, 2000
19. Current good manufacturing practice (CGMP) for positron emission tomography drug products. Fed Regist 74:65409, 2009
20. Guidance on PET drugs: current good manufacturing practice. Fed Regist 74:65538, 2009
21. Harapanhalli RS: Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals. Semin Nucl Med 40:364-384, 2010
22. Park KB, Kitteringham NR, O'Neill PM: Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 41:443-470, 2001 (Pubitemid 32385895)
23. 18F radiopharmacy. Ernst Schering Res Found Workshop 62:215-242, 2007
24. Zhernosekov KP, Filosofov DV, Baum RP, et al: Processing of generator- produced 68 Ga for medical application. J Nucl Med 48:1741-1748, 2007 (Pubitemid 47572722)
25. 68Ga generator has high potential, but when can we use 68 Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging 34:978-981, 2007
26. Williams HA, Robinson S, Julyan P, et al: A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med Mol Imaging 32:1473-1480, 2005 (Pubitemid 41746853)
27. Holland JP, Phil D, Sheh Y, et al: Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36:729-739, 2009
28. Wu AM: Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50:2-5, 2009
29. Rice SL, Roney CA, Daumar P, et al: The next generation of PET radiopharmaceuticals in oncology. Semin Nucl Med 41:265-282, 2011
30. 68Ga-labeled radiopharmaceuticals for PET. Semin Nucl Med 41:315-322, 2011
31. Vallabhajosula S: PET radiopharmaceuticals for imaging brain beta amyloid (Aβ). Semin Nucl Med 41:283-299, 2011
32. Lister-James, Pontecorvo MJ, Clark C, et al. Florbetapir F-18: a histopathologically- validated β-amyloid PET imaging agent. Semin Nucl Med 41:300-304, 2011
33. Yu M, Nekolla SG, Schwaiget M, et al: The next generation of cardiac PET imaging agent: discovery of Flurpiridaz F 18 for detection of coronary disease. Semin Nucl Med 41:305-313, 2011
34. Graham MM: The Clinical Trials Network of the Society of Nuclear Medicine. Semin Nucl Med 40:327-331, 2010
35. Blau M, Nagler W, Bender MA: A new isotope for bone scanning. J Nucl Med 3:332-334, 1962
36. 99mTc-methylene diphosphonate. Semin Nucl Med 31:28-49, 2001
37. Even-Sapir E, Mishani E, Flusser G, et al: 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 37:462-469, 2007 (Pubitemid 47505220)
38. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 49:68-78, 2008
39. Segall G, Delbeke D, Stabin MG, et al: SNM practice guideline for sodium 18 F-fluoride PET/CT bone scans 1.0. J Nucl Med 51:1813-1819, 2010
40. Drzezga A: Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. Eur J Nucl Med Mol Imaging 35(Suppl 1):S4-S11, 2008
41. Forman MS, Mufson EJ, Leurgans S, et al: Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 68:757-673, 2007
42. Mathis CA, Lopresti BJ, Klunk WE: Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34:809-822, 2007 (Pubitemid 47503823)
43. Thal LJ, Kantarci K, Reiman EM, et al: The role of biomarkers in clinical trials for Alzheimer disease and associated disorders. Alzheimer Dis Assoc Disord 20:6-15, 2006 (Pubitemid 44356888)
44. 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2754, 2003
45. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55: 306-319, 2004 (Pubitemid 38269583)
46. Kung M-P, Hou C, Zhuang Z-P, et al: Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 1025:98-105, 2004 (Pubitemid 39359172)
47. Zhang W, Oya S, Kung MP, et al: F-18 stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain. J Med Chem 48:5980-5988, 2005 (Pubitemid 41324608)
48. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 50:1887-1894, 2009
49. Clark CM, Schneider JA, Bedell BJ, et al: Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 305:275-283, 2011
50. Kolata G: F.D.A. Sees Promise in Alzheimer's Imaging Drug, The New York Times, January 20, 2011
51. 1F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129-135, 2008
52. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50:818-822, 2009
53. Nelissen N, Laere KV, Thurfjell L, et al: Phase 1 study of the Pittsburgh compound B derivative 18 F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 50:1251-1259, 2009
54. Vandenberghe R, Van Laere K, Ivanoiu A, et al: 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319-329, 2010
55. Klunk WE, Mathis CA: The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 21:683-687, 2008
56. Kilbourn MR: In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 24:615-619, 1997
57. Frey KA, Koeppe RA, Kilbourn MR, et al: Presynaptic monoaminergic vesicles in Parkinsons's disease and normal aging. Ann Neurol 40: 873-884, 1996 (Pubitemid 27044605)
58. Kung M-P, Hou C, Goswami R, et al: Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 34:239-246, 2007 (Pubitemid 46441853)
59. Rowe C: SNM highlights lecture: neuroscience. J Nucl Med 51(Suppl 2):31N-37N, 2010
60. Kung MP, Hou C, Lieberman BP, et al: In vivo imaging of beta-cell mass in rats using 18 F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 49:1171-1176, 2008
61. Harris PE, Ferrara C, Barba P, et al: VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med 86:5-16, 2008
62. 11C]- dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur J Nucl Med Mol Imaging 35:790-797, 2008
63. 18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med 51:1480-1485, 2010
64. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50:382-389, 2009
65. FagerholmV, Mikkola KK, Ishizu T, et al: Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat and human pancreas. J Nucl Med 51:1439-1446, 2010
66. Ghosh N, Rimoldi OE, Beanlands RSB, et al: Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J 31:2984-2995, 2010
67. Camici PG, Rimoldi OE: The clinical value of myocardial blood flow measurement. J Nucl Med 50:1076-1087, 2009
68. Schwaiger M, Bengel FM: From thallium scan to molecular imaging. Mol Imaging Biol 4:387-398, 2003 (Pubitemid 36221806)
69. Berman DS, Shaw LJ, Hachamovitch R, et al: Comparative use of radionuclide stress testing, coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and prognostic cardiac assessment. Semin Nucl Med 37:2-16, 2007 (Pubitemid 44854758)
70. Schelbert HR: Positron emission tomography of the heart: methodology, findings in the normal and disease heart, and clinical applications, in Phelps ME (ed): PET: Molecular Imaging and Its Clinical Applications. New York, Springer, 2004
71. Lin JW, Sciacca RR, Chou RL, et al: Quantification of myocardial perfusion in human subjects using 82 Rb and wavelet-based noise reduction. J Nucl Med 42:201-208, 2001 (Pubitemid 32150509)
72. 99mTc-sestamibi. J Nucl Med 42:272-281, 2001
73. Madar I, Ravert HT, Du Y, et al: Characterization of uptake of the new PET imaging compound 18 F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med 47:1359-1366, 2006 (Pubitemid 47544892)
74. Yalamanchili P, Wexler E, Hayes M, et al: Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol 14:782-788, 2007 (Pubitemid 350082573)
75. 18F]-RP1012: a novel myocardial perfusion imaging agent for use with positron emission tomography (PET). Circulation 112:II-761, 2005
76. Yu M, Guaraldi MT, Mistry M, et al: BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol 14:789-798, 2007 (Pubitemid 350082572)
77. 18F-labeled myocardial perfusion tracer. J Nucl Med 49:630-636, 2008
78. Schwaiger M: SNM highlights lecture: cardiovascular disease. J Nucl Med 51(Suppl 2):15N-19N, 2010
79. 18F]1-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumors. J Nucl Med 40:331-338, 1999
80. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48:56-63, 2007
81. Chen W: Clinical applications of PET in brain tumors. J Nucl Med 48:1468-1481, 2007
82. Larson SM: SNM highlights lecture: oncology. J Nucl Med 51(Suppl 2):19N-25N, 2010
83. 18F]fluorocyclobutane-1-carboxylic acid (anti- [18F]FACBC) PET-CT in recurrent prostate carcinoma. J Nucl Med 51(Suppl 2):456, 2010
84. 18F] Fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem 54:406-410, 2011
85. 18F]BAY 85-8050 (TIM-1): a novel tumor specific probe for PET/CT imaging - first clinical results. J Nucl Med 51(Suppl 2):118, 2010
86. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4:123-131, 2003
87. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct αV integrins. Science 270:1500-1502, 1995 (Pubitemid 3005294)
88. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40:1061-1071, 1999
89. 18F]galacto-RGD. PLoS Med 2:e70, 2005
90. Line BR, Mitra A, Nan A, et al: Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates J Nucl Med 46: 1552-1560, 2005
91. Kenny LM, Coombes RC, Oulie I, et al: Phase I trial of the positron-emitting ArgGlyAsp (RGD) peptide radioligand 18 F-AH111585 in breast cancer patients. J Nucl Med 49:879-886, 2008 (Pubitemid 351793427)
92. Indrevoll B, Kindberg GM, Solbakken M, et al: NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett 16:6190-6193, 2006 (Pubitemid 44709917)
93. 18F]fluciclatide (AH111585). J Nucl Med 51(Suppl 2):505, 2010
94. Szabo Z, Alachkar N, Xia J, et al: Molecular imaging of the kidneys. Semin Nucl Med 41:20-28, 2011
95. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8:304-310, 2007
96. Cleaver JE: Thymidine metabolism and cell kinetics. Front Biol 6:43-100, 1967
97. Christman D, Crawford EJ, Friedkin M, et al: Detection of DNA synthesis in intact organisms with positron-emitting methyl- [C-11]-thymidine. Proc Natl Acad Sci U S A 69:988-992, 1972
98. 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44:1432-1434, 2003
99. Bading JR, Shields AF: Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S-80S, 2008
100. 18F]fluorothymidine. Semin Nucl Med 37:429-439, 2007
101. Conti PS, Bading JR, Mouton P, et al: In vivo measurement of cell proliferation in canine brain tumor using C-11 labeled FMAU and PET. Nucl Med Biol 35:131-141, 2008
102. Sun H, Sloan A, Mangner T, et al: Imaging DNA synthesis in vivo with [F-18]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 32:15-22, 2005 (Pubitemid 40142774)
103. Krohn KA, Link JM, Mason RP: Molecular imaging of hypoxia. J Nucl Med 49(Suppl 2):129S-148S, 2008
104. Foo SS, Abbott DF, Lawrentschuk N, et al Functional Imaging of intra-tumoral hypoxia. Mol Imaging Biol 6:291-305, 2004
105. Rasey JS, Grunbaum Z, Magee S, et al: Characterization of radio-labeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 111:292-304, 1987 (Pubitemid 17156952)
106. Mees G, Dierckx R, Vangestel C, et al: Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 36:1674-1686, 2009
107. Lee ST, Scott AM: Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 37:451-461, 2007 (Pubitemid 47498258)
108. Fujibayashi Y, Taniuchi H, Yonekura Y, et al: Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155-1160, 1997 (Pubitemid 27339632)
109. Maurer RI, Blower PJ, Dilworth JR, et al: Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45:1420-1431, 2002 (Pubitemid 34246105)
110. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40:177-183, 1999
111. Lewis JS, Welch MJ: PET imaging of hypoxia. Q J Nucl Med 45:183-188, 2001 (Pubitemid 32651665)
112. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427, 2003
113. Reubi JC, Laissue J, Krenning EP, et al: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication. J Steroid Biochem Mol Biol 43:27-35, 1992
114. Reubi JC, Mäcke HR, Krenning EP: Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46(Suppl 1):67S-75S, 2005
115. 68Ga-labeled peptides in tumor imaging. J Nucl Med 46(Suppl 1):172S-178S, 2005
116. Rufini V, Calcagni ML, Baum RP: Imaging of neuroendocrine tumors. Semin Nucl Med 36:228-247, 2007
117. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007:508-518, 2007
118. 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67-77, 2010
119. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004-2010, 2010
120. Jacobs AH, Winkler A, Castro MG, et al: Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging 32(Suppl 2):S358-S383, 2005 (Pubitemid 41799555)
121. 2O. J Nucl Med 45:1851-1859, 2004
122. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518, 2007